Telix Pharmaceuticals (NASDAQ:TLX) Hits New 1-Year High – What’s Next?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) hit a new 52-week high during trading on Wednesday . The stock traded as high as $12.48 and last traded at $12.3940, with a volume of 393964 shares changing hands. The stock had previously closed at $11.98.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TLX. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Down 4.7%

The stock has a fifty day simple moving average of $11.24 and a 200-day simple moving average of $10.13. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the second quarter valued at approximately $975,000. Jane Street Group LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $564,000. IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $213,000. Rhumbline Advisers boosted its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.